Keon Torres, Ulcerative Colitis Patient

About the Association

AAM works to ensure more generic and biosimilar medicines are accessible to the people who need them.

The Association for Accessible Medicines improves access to safe, quality and effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

  • Driving down the costs of existing drugs and developing new ones means people can afford the medicines they need.
  • Increasing competition means payers and patients have a choice in the marketplace.
  • Working to get safe, effective, and more-affordable medicines out of the lab and into the hands of the people who need them is a goal that touches not just individuals and families, but the overall economy, and the entire nation.

As manufacturers of 9 out of every 10 prescriptions dispensed in the U.S., members of the Association for Accessible Medicines form an integral, and powerful, part of the health care system.

Learn More: Voices of Access

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Recent News

AAM Tweets

Team & Board

AAM works to ensure more generic and biosimilar medicines are accessible to the people who need them.

The Association for Accessible Medicines improves access to safe, quality and effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Generics and biosimilars help more people in more places live healthier and longer.

  • Driving down the costs of existing drugs and developing new ones means people can afford the medicines they need.
  • Increasing competition means payers and patients have a choice in the marketplace.
  • Working to get safe, effective, and more-affordable medicines out of the lab and into the hands of the patients who need them in pacts, public health and national security.

As manufacturers of 9 out of every 10 prescriptions dispensed in the U.S., members of the Association for Accessible Medicines form an integral, and powerful, part of the health care system.

Generic and biosimilar medicines have an enormous impact at an extremely minimal relative cost, proving our industry to be a stable backbone for the U.S. healthcare system.”

John Murphy III, President and CEO of AAM

Team & Board

Dedicated to improved access to safe, quality and effective medicine.

AAM’s commitment echoes that of our member companies. Generic and biosimilar drugmakers have active corporate social responsibility programs that you can learn more about here and here.

Partnering with Suppliers of Medication

AAM collaborates locally and nationally with organizations that share our values and commitment. We support the work of our associate members who are advancing community health.

Promoting Health and Well-Being

AAM recognizes that the issue of health goes beyond access to medication. We support organizations that contribute to targeted determinants of health.

Central Union Mission is the oldest private social service agency in Washington, DC. AAM staff volunteers at the mission, including annually assembling and donating health kits for residents

Maintaining a Code of Business Ethics

The practices discussed in AAM’s code of ethics represent behaviors our companies have been demonstrating for many years. And yet it is incumbent on us to declare to our patients and customers the values upon which our industry is based, and the ethical and business standards upon which we are committed to operating with other members of the healthcare ecosystem